Just out! We challenge the prevailing caution and advocate for a biomarker-guided approach soon to be tested in the STRATIFY lupus trial: Rituximab–belimumab combination for refractory SLE #lupus#PrecisionMedicine@MuhammadShipa @VersusArthritis
https://t.co/sP07zmYEmh
Are you a rheumatologist or nephrologist looking after patients with #lupus#nephritis in the UK?
We would like to invite you to take part in our research study to understand how treatment decisions are made.
https://t.co/4opHvblWmt
@lupusUK@UKKidney
Validation and mechanistic insights for IgA2 as a companion biomarker of combination belimumab after rituximab for #lupus supporting the upcoming STRATIFY lupus trial https://t.co/vGOvP8Xgsa
A very productive 2-Day #BILAG#lupus meeting in Leeds to enhance recruitment of @NIHRresearch FIRST and @VersusArthritis @NIHRresearch@The_MRC STRATIFY-LUPUS - two trials opening in UK in 2026. Discussed Treat-to-Target & inspiring the next generation Lupus Leaders @LUPUSUK 🦋
STRATIFY lupus: personalised care for patients | NIHR- a big thank you to all the lupus specialists and their patients who made this research possible as well as @VersusArthritis and @GSK https://t.co/DxEWOyE5GN
📷🎉Exciting news!
Mike and I have been awarded a new grant to lead the STRATIFY Lupus—the FIRST EVER biomarker-enriched trial in lupus!
We’ll use biomarkers (IgA2 anti-DNA) to predict who responds best to treatment. @VersusArthritis, @NIHRresearch EME, @GSK , and @LUPUSUK
NEW REVIEW—@LucyCarter6, @MikeEhrenstein & @edvital discuss the evolution and trajectory of B-cell targeted therapies in rheumatic diseases https://t.co/ptfLhlIPAR
And a big shout out to @MuhammadShipa who has helped to make the STRATIFY lupus trial possible and will be joining @DoM_UCL as a Principal Research Fellow and consultant rheumatologist.
Thanks to @VersusArthritis and NIHR who have just agreed to jointly provide £1.7M to support a precision medicine trial in #lupus. Thanks to @GSK for providing free belimumab, and to all the UK lupus experts for agreeing to help recruit patients. #WorldLupusDay @NIHR_Industry
Important research from @Dr_JohnR and colleagues highlighting the differences in management approaches for #lupus nephritis within the UK and that rituximab remains the most popular choice for refractory renal disease https://t.co/vcxziBuN7j
Very proud of @MuhammadShipa who successfully defended his thesis this afternoon. Well done! Thanks to @VersusArthritis and @LUPUSUK for supporting his research.
Clinical trials provide a unique substrate to understand pathogenesis and identify biomarkers to targeted therapies in #SLE which can be used to stratify patients. Taken from a new Viewpoint by @MikeEhrenstein and @MuhammadShipa: https://t.co/JcwXz7qTsQ